Logo

Pusat Sumber Belajar FEB UI

  • FAQ
  • Berita
  • Rooms
  • Bantuan
  • Area Anggota
  • Pilih Bahasa :
    Bahasa Inggris Bahasa Indonesia
  • Search
  • Google
  • Advanced Search
*sometimes there will be ads at the top, just scroll down to the results of this web
No image available for this title

Text

Bad medicine: Litigation, competition, and the marketing of prescription opioids

Tan, David - ; West, Nicole V. - ;

Research Abstract: How do competitors respond when a firm experiences an increased threat of penalties for questionable business activities? While conventional wisdom suggests that competitors will attempt to avoid similar activities, we draw attention to a countervailing incentive. If an increased threat of penalties induces one firm to reduce its engagement in an activity, competitors in an industry may see an opportunity to profit by increasing their engagement in the activity. We explain how this is theoretically possible even if competitors also experience an increased threat of penalties. As an empirical example, we show that following a lawsuit against Purdue Pharma, Purdue significantly decreased its spending to promote OxyContin, but other prescription opioid firms significantly increased their spending to promote competing opioids to the same physicians.

Managerial Abstract: Competitive dynamics can make questionable business activities in an industry difficult to stamp out on a case-by-case basis. Forcing one firm to decrease its engagement in a questionable activity may result in competitors stepping in to fill the void by increasing their engagement in similar activities. We find that this occurred in the prescription opioid industry. Following a lawsuit against Purdue Pharma, Purdue significantly decreased its spending to promote its controversial OxyContin product. But rather than attempt to distance themselves from association with Purdue, other prescription opioid firms significantly increased their spending to promote competing opioids to physicians previously targeted by Purdue, including in counties where the opioid epidemic was known to be severe.


Ketersediaan

Call NumberLocationAvailable
PSB lt.2 - Karya Akhir (Majalah)1
PenerbitUSA: Strategic Management Society 2023
EdisiVol. 44 Issue 11, Nov 2023
SubjekCompetition
Pharmaceutical industry
Litigation
Stigma
Nonmarket strategy
ISBN/ISSN1097-0266
KlasifikasiNONE
Deskripsi Fisik235 p.
Info Detail SpesifikStrategic Management Journal
Other Version/RelatedTidak tersedia versi lain
Lampiran Berkas
  • Bad medicine: Litigation, competition, and the marketing of prescription opioids

Pencarian Spesifik
Where do you want to share?